FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis

53Citations
Citations of this article
97Readers
Mendeley users who have this article in their library.

Abstract

This review describes the recently FDA-approved drugs (in the year 2022). Many of these products contain active moieties that FDA had not previously approved, either as a single ingredient or as part of a combination. These products frequently provide important new therapies for patients with multiple unmet diseases. The diverse small molecules are described according to the date of approval and their syntheses is discussed. This review comprises classical chemical scaffolds together with innovative drugs such as a deuterium-containing drug.

Author supplied keywords

Cite

CITATION STYLE

APA

Tiz, D. B., Bagnoli, L., Rosati, O., Marini, F., Santi, C., & Sancineto, L. (2022, November 1). FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis. Pharmaceutics. MDPI. https://doi.org/10.3390/pharmaceutics14112538

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free